Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

17.60
+1.489.18%
Post-market: 17.45-0.1501-0.85%19:53 EDT
Volume:24.31M
Turnover:420.93M
Market Cap:20.19B
PE:-12.14
High:17.69
Open:16.69
Low:16.60
Close:16.12
Loading ...

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

Zacks
·
20 Dec 2024

Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?

Insider Monkey
·
19 Dec 2024

Stock Track | Teva Pharmaceutical Soars 5% on Positive Study Data For Investigational IBD Drug

Stock Track
·
19 Dec 2024

Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says

MT Newswires Live
·
19 Dec 2024

BofA Securities Raises Price Target on Teva Pharmaceutical Industries to $25 From $23, Keeps Buy Rating

MT Newswires Live
·
18 Dec 2024

Teva : Bofa Global Research Raises Price Objective to $25 From $23

THOMSON REUTERS
·
18 Dec 2024

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Zacks
·
18 Dec 2024

Teva price target raised to $28 from $26 at UBS

TIPRANKS
·
18 Dec 2024

Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?

Zacks
·
18 Dec 2024

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (A) and Teva Pharmaceutical (TEVA)

TIPRANKS
·
18 Dec 2024

Teva price target raised to $28 from $25 at Barclays

TIPRANKS
·
18 Dec 2024

Teva Pharmaceutical (TEVA) Gets a Hold from J.P. Morgan

TIPRANKS
·
18 Dec 2024

Equity Markets Fall as Fed Meeting Gets Underway

MT Newswires Live
·
18 Dec 2024

TD says Spyre has ‘superior TL1A program’ after Teva data

TIPRANKS
·
18 Dec 2024

Teva and Sanofi (SNY) Jump amid Impressive Drug Results

TIPRANKS
·
18 Dec 2024

Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG

TIPRANKS
·
18 Dec 2024

Sector Update: Health Care Stocks Mixed Tuesday Afternoon

MT Newswires Live
·
18 Dec 2024

Teva price target raised to $25 from $23 at BofA

TIPRANKS
·
18 Dec 2024

Update: Teva, Sanofi Shares Jump as Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

MT Newswires Live
·
18 Dec 2024

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations

GuruFocus.com
·
18 Dec 2024